Treatment Costs of Adjuvant Cytotoxic Therapy in Premenopausal Breast Cancer Patients

Authors

  • J. Løber Department of Oncology Ona, The Finsen Institute, Rigshospitalet, And the Medical Importers' Association, Copenhagen, And the Institute of Social Medicine, University of Aarhus, Aarhus, Denmark
  • J. Søgaard Department of Oncology Ona, The Finsen Institute, Rigshospitalet, And the Medical Importers' Association, Copenhagen, And the Institute of Social Medicine, University of Aarhus, Aarhus, Denmark
  • H. T. Mouridsen Department of Oncology Ona, The Finsen Institute, Rigshospitalet, And the Medical Importers' Association, Copenhagen, And the Institute of Social Medicine, University of Aarhus, Aarhus, Denmark
  • J. Jørgensen Department of Oncology Ona, The Finsen Institute, Rigshospitalet, And the Medical Importers' Association, Copenhagen, And the Institute of Social Medicine, University of Aarhus, Aarhus, Denmark

DOI:

https://doi.org/10.3109/02841868809091783

Keywords:

Breast cancer, adjuvant chemotherapy, costs

Abstract

Abstract

The interest in cost calculations of medical treatment programs has increased during the last decade. In the Danish Breast Cancer Cooperative Group's (DBCG) protocol 77B, 1 028 premenopausal patients were randomized after mastectomy to radiotherapy (RT) alone (control), RT + 12 cycles of cyclophosphamide (C) or to RT + 12 cycles of cyclophosphamide, methotrexate and 5-fluoro-uracil (CMF). This study analyzes the costs associated with systemic treatment and follow-up programs in the 3 regimens. Costs connected with the primary mastectomy and the radiotherapy, which were identical in the 3 regimens, have not been included in the analysis. The analysis shows that the expenses for the postoperative treatment and follow-up program for 9 years in the control regimen are 8 250 DKK, whereas the costs for the C regimen are 11000 DKK, and the costs for the CMF regimen are 18000 DKK.

Downloads

Download data is not yet available.

Downloads

Published

1988-01-01

How to Cite

Løber, J., Søgaard, J., Mouridsen, H. T., & Jørgensen, J. (1988). Treatment Costs of Adjuvant Cytotoxic Therapy in Premenopausal Breast Cancer Patients. Acta Oncologica, 27(6), 767–771. https://doi.org/10.3109/02841868809091783

Issue

Vol. 27 No. 6 (1988): Acta Oncologica

Section

Articles